To assess the expression level of fms-like tyrosine kinase 3 (FLT3), the incidence of FLT3/internal tandem duplications (ITD) mutation, and prognostic value of FLT3 changes in different types of adult leukemia.
Methods Bone marrow mononuclear cells were isolated from 147 adult patients with leukemia. Reverse transcriptase polymerase chain reaction (PCR) was used to screen FLT3/ITD mutation and quantitative PCR was performed to evaluate the expression of the FLT3 transcript. Flow cytometry was used for detection of FLT3 receptor protein expression on bone marrow mononuclear cells. Pearson correlation analysis was performed to estimate the significance of FLT3.
Results FLT3 expression was higher in acute myeloid leukemia and Bacute lymphoid leukemia than in T-acute lymphoid leukemia (P = 0.006, P = 0.001) and chronic myelogenous leukemia (P < 0.001). In chronic myelogenous leukemia, FLT3 expression in blast transformation phase was higher than in acceleration phase (P = 0.023). Surface expression of FLT3 protein was correlated with high percentage of bone marrow blasts and with FLT3 mRNA expression (r = 0.366, P < 0.001) in acute leukemia. FLT3/ITDs in the juxtamembrane domain were found in 25% of patients with acute myeloid leukemia and 7% of patients with acute lymphoid leukemia. FLT3/ITD positive sequences had 36, 42, and 57 nucleotides. FLT3/ITD mutation was associated with a higher white blood cell count, higher marrow blast percentage, and elevated serum lactate dehydrogenase (P = 0.045, P = 0.014, P < 0.001, respectively) and not associated with a higher FLT3 mRNA and FLT3 protein expression, and lower complete remission (P = 0.091, P = 0.060, P = 0.270, respectively).
Conclusion FLT3 expression levels differed in different types of adult leukemia. Overexpression of FLT3 and presence of a positive FLT3/ ITD mutation in acute leukemia were associated with unfavorable clinical characteristics and poor prognosis.
The fms-like tyrosine kinase 3 (FLT3) gene belongs to the class III receptor tyrosine kinases and is predominantly expressed on hematopoietic progenitor cells in the bone marrow, thymus, and lymph nodes (1) . An abnormality in the FLT3 gene is implicated in the pathogenesis of acute myeloid leukemia (2) (3) (4) . Approximately 25% of patients with adult acute myeloid leukemia harbor internal tandem duplications (ITD) within the juxtamembrane domain of the FLT3 gene (5, 6) . FLT3/ITDs cause structural changes in the juxtamembrane and this disrupts the autoinhibitory conformation of the receptor (7) by promoting constitutive activation of both receptor (8) (9) (10) and downstream effectors, which all leads to a bad prognosis (11, 12) . In the last decade, FLT3/ITD mutations have been reported in 13%-32% of adult patients with acute myeloid leukemia and in a small number of patients with acute lymphoid leukemia (13) (14) (15) (16) . Patients with this abnormality have increased incidence of leukocytosis and decreased overall survival in comparison with patients without this abnormality. These findings indicate that FLT3/ITDs not only play an important role in the pathogenesis mechanism of leukemia but also have a prognostic value.
A previous study has demonstrated that high levels of FLT3 were expressed in leukemia and lymphoma cell lines including pre-B, myeloid, and monocytic cell lines (17) . Also, several studies have shown that high levels of FLT3 were expressed in 70%-100% of patients with acute myeloid leukemia and Bacute lymphoid leukemia and in about 30% of patients with T-acute lymphoid leukemia (18, 19) . Likewise, a small number of chronic myelogenous leukemia blast crisis and chronic lymphocytic leukemia cells has been shown to express FLT3 (18, 20) . These data indicate that FLT3 expression may play a role in the survival or proliferation of leukemic blasts. Using Western blotting, Carow et al (18) found no FLT3 expression in the normal bone marrow, but identified FLT3 protein in 14 of 14 B-cell acute lymphoid leukemia cases, 36 of 41 acute myeloid leukemia cases, and 1 of 4 T-cell acute lymphoid leukemia cases. Though FLT3 expression in leukemia and its clinical significance have been widely investigated, little is known about FLT3 expression level and its clinical significance in Chinese patients with adult leukemia. Most of the studies have used Western blot assay as FLT3 protein assay, whereas flow cytometry on intact leukemic cell surface has been rarely used. We used flow cytometry on cell surface to investigate the expression of FLT3 receptor and quantitative polymerase chain reaction (PCR) to investigate FLT3 mRNA expression, as well as performed identification of FLT3/ITDs in different types of adult leukemia.
Patients and methods
The study included 120 patients with newly diagnosed acute leukemia -60 with acute myeloid leukemia, 30 with B-acute lymphoid leukemia, 30 with T-acute lymphoid leukemia; 27 with chronic myeloid leukemia; and 30 controls (Table 1) . Diagnosis was based on May-Grunwald-Giemsa-stained bone marrow smears and cytochemistry performed according to the French-American-British (FAB) group criteria (21). Leukocyte differentiation antigens were analyzed by immunofluorescent method for some cases. Complete remission was defined as normocellular bone marrow containing less than 5% blasts and showing evidence of normal maturation of other bone marrow elements. Patients and controls provided informed consent to use their samples for this study.
mRNA expression analysis
Patients and controls' bone marrow mononuclear cells were separated on a Ficoll-Hypaque density gradient. Total RNA was extracted from bone marrow mononuclear cells by using Trizol Kit (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized from each RNA by a random primer and Moloney murine leukemia virus reverse transcriptase (Promage, Madison, WI, USA) according to the manufacturer's recommendations. FLT3 gene expression was assessed by reverse transcriptase PCR (RT-PCR) and quantitative PCR. The primer pairs of FLT3 for RT-PCR were 5′-TGTCGAGCAGTACTCTAAACA-3′ and 5′-ATCCTAGTACCTTCCCAAACTC-3′ (22) . The β-actin gene, with primers 5′-TGACGGGGTCACCCACAC-3′ and 5′-CTAGAAGCATTTGCGGTGGA-3′, served as an internal control. Reagents consisted of Taq polymerase, dNTP, buffer, and MgCl 2 . Reaction was performed in three steps as follows: denaturation at 94°C, annealing at 50°C, and elongation at 72°C. After 35 cycles, PCR products were fractionated through 2.5% agarose gels and viewed under UV illumination after ethidium bromide staining.
Expression of FLT3 mRNA was analyzed with quantitative PCR in 20 controls and 50 patients with acute myeloid leukemia (16 acute myeloblastic leukemia with maturation; 12 acute promyelocytic leukemia; 5 acute myelomonocytic leukemia; 15 acute monocytic leukemia; 2 acute erythroid leukemia), 20 patients with B-acute lymphoid leukemia, 20 patients with T-acute lymphoid leukemia, and 27 patients with chronic myelogenous leukemia. Quantitative PCR was done by Quantitect SYBR green PCR reagent (Qiagen, Miami, FL, USA) following the manufacturer's recommendations and using a quantitative PCR instrument RotorGene 6000 (Corbett Research, Mortlake, Australia). The primer sequences of FLT3 were forward -5′-TCAAGTGCT-GTGCATACAATTCCC-3′ and reverse -5′-CACCTGTACCATCTGTAGCT-GGCT-3′; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a reference with the following sequences: forward -5′-CCAAAATCAAGTGGGGCGATG-3′ and reverse -5′-AAAGGTGGAGGAGTGGGT-GTCG-3′ (23). Thermal cycling for FLT3 was performed as follows: step 1 -at 95°C for 15 minutes; step 2 -at 95°C for 15 seconds; step 3 -at 50°C for 30 seconds, step 4 -at 72°C for 1 minute. Steps 2-4 were repeated for 35 cycles. The copy number of each sample was calculated by relative quantification. A dilution series of 5 different concentrations was used to generate two standard curves, one for FLT3 and another for GAPDH. FLT3 and GAPDH were simultaneously amplified and the threshold cycle (Ct) of each gene was obtained. Ct values of the sample and the corresponding standard curve were used to calculate the amounts of GAPDH and FLT3 mRNA. FLT3 mRNA expression was then presented as ratio of FLT3/GAPDH mRNA in the sample, as the expression of GAPDH was constant across samples.
Screening for mutation of FLT3/ITD
Amplified products were resolved on 2.5% agarose gels. FLT3/ITD mutations were 
Results

Expression of FLT3 transcript in leukemia
RT-PCR combined with gel-image analysis system was used to determine the expression of FLT3 transcript in 147 patients with leukemia and 30 controls. Of 147 patients, there were 120 patients with acute leukemia and 27 patients with chronic myelogenous leukemia. Of these, 138 (93.9%) showed FLT3 mRNA expression (117 patients with acute leukemia and 21 with chronic myelogenous leukemia). Quantitative PCR showed that FLT3 mRNA was expressed in 90 patients with acute leukemia, 27 patients with chronic myelogenous leukemia, and 20 controls ( Figure  1 ). There was a significant difference between patients with acute myeloid leukemia and patients with chronic myelogenous leukemia in FLT3expression (Figure 1 ). In patients with acute myeloid leukemia, B-acute lymphoid leukemia, and T-acute lymphoid leukemia, mean percentage of blasts was 61.0%, 56.5%, 55.8%, respectively, and the expression level in acute myeloid leukemia and B-acute lymphoid leukemia was significantly higher than in Tacute lymphoid leukemia. In chronic myelog- enous leukemia, the expression of FLT3 transcript was associated with disease progression of transformation ( Table 2) .
Incidence of FLT3/ITD mutation in acute leukemia
Of 60 patients with acute myeloid leukemia, 15 had FLT3/ITD mutation. Patients with acute monocytic leukemia had higher FLT3/ ITD mutation rate than patients with other FAB types (Table 3) . Of 60 patients with acute lymphoid leukemia, 4 had FLT3/ITD mutations. No FLT3/ITD mutation was found in chronic myelogenous leukemia. Sequence analysis performed in 3 FLT3/ITD mutations showed that mutations involved exon 14, the sizes of the inserting nucleotides were 36, 42, and 57 pairs, and all had tandem duplication. The location of each mutation also varied, with the ITD in two patients starting at codon 597 and in another patient at codon 603. The deduced amino acid sequences for FLT3/ITD mutation are shown in Figure 2 .
Characteristics of patients with FLT3/ITD mutation
Nineteen of 120 patients with acute leukemia had FLT3/ITD mutation ( Table 4 ). The presence of the mutation was not related to sex or age. However, it was associated with a higher peripheral white blood cell count and a higher percentage of blasts in the bone marrow at diagnosis. Patients with acute leukemia with FLT3/ITD had significantly higher serum LDH concentration than patients with acute leukemia without FLT3/ITD. As to the expression level, FLT3 transcript in 12 patients with tandem duplication was upregulated, but the difference was not significant. The expressive signal of FLT3 protein in patients with acute leukemia with FLT3/ ITD mutation was stronger than in patients with acute leukemia without FLT3/ITD mutation. The complete remission rate for 120 patients with acute leukemia in this study was 82.5%. Patients with FLT3/ITD mutation had lower complete remission rate than patients without FLT3/ITD mutation (73.68% vs 84.16%), although the relationship was not significant.
FLT3 receptor expression and its correlation with bone marrow blasts
Mean expression level (percentage of FLT3 positive cells) of FLT3 protein in controls was 2.20 ± 1.06%, which was significantly lower than in patients with leukemia (17.38 ± 9.45%, P < 0.001) ( Table 2 ). The expression of FLT3 was significantly higher in patients with acute leukemia (18.82 ± 9.66%) than in patients with chronic myelogenous leukemia in chronic (6.74 ± 1.85%, P < 0.001) and acceleration phase (10.11% ± 1.92, P = 0.019), but no significant difference was observed in comparison with patients in the blast transformation phase (15.81% ± 3.02, P = 0.307). In the acute leukemia group, Pearson correlation analysis showed that the percentage of FLT3-positive cells was significantly related to blast count ( Figure 3 ). The expression of FLT3 transcript was correlated with that of FLT3 receptor protein ( Figure 4 ).
Discussion
Our study showed that FLT3 mRNA was expressed in all patients with B-acute lymphoid leukemia and acute myeloid leukemia and 90% of patients with T-acute lymphoid leukemia. Compared with controls, the mean expression level of the FLT3 transcript in acute lymphoid leukemia and acute myeloid leukemia was evidently increased. This is in close agreement with previously published results (18, 20) . Due to a limited number of acute myeloid leukemia cells available for this analysis, we did not investigate the correlations with FAB type and cytogenetics, which had previously been demonstrated as important factors for outcome of acute myeloid leukemia (5, 6, 11, 15) . Larger scale investigations on the associations between FLT3 expression level and cytogenetics should be performed in future research. We found FLT3 mRNA and protein expression in chronic myelogenous leukemia, which is consistent with the results by Carow et al (18) . Compared with the chronic phase of chronic myelogenous leukemia, 7 patients in the acceleration phase had significantly increased white blood cell count and number of blasts in the bone marrow, but not the expression level of the FLT3 transcript. Also, patients in the acceleration phase had significantly higher surface expression of FLT3 receptor protein than patients in the chronic phase. In chronic myelogenous leukemia, FLT3 protein expression increased more than mRNA expression. This was different than in acute leukemia, probably because FLT3 mRNA level is associated with cell types and stage of blast maturation and perhaps has an unknown biological cause. Although larger scale analysis is required to clarify the clinical significance of increased FLT3 expression, we believe that FLT3 expression may contribute to chronic myelogenous leukemia disease progression and that its estimation may be helpful for identification of chronic myelogenous leukemia blast transformation. This is in accordance with the study by Lin et al (24) , who detected FLT3 gene mutations in chronic myeloproliferative diseases and found FLT3 mutations correlated with an increased number of blasts. FLT3 may participate in blast transformation in chronic myeloproliferative diseases, including chronic myelogenous leukemia.
No data have been available on the expression of FLT3 protein in acute leukemia. We found that the surface expression of FLT3 receptor protein in bone marrow mononuclear cells was related to FLT3 mRNA. This is in line with the findings of Kuchenbauer et al (25) , who reported that CD135 receptor expression was correlated with FLT3 mRNA. On the other hand, Ozeki et al (26) found that surface expression level of FLT3 was not related to the expression of the FLT3 transcript. This might be due to the fact that they analyzed a limited number of acute myeloid leukemia samples. Kuchenbauer et al (27) reported higher Spearman rank correlation than we did, probably because they used direct conjugated antibody. As to the mechanism of FLT3 protein overexpression, they suggested an autocrine stimulatory mechanism of FLT3 receptor-ligand (FL). FLT3-FL loop, which is expressed in all cell lines, plays an important role in the pathobiology of leukemia. Combined with various cytokines, FL has synergistic or additive mitogenic effect, which leads to significant anti-apoptotic effects on primary acute myeloid leukemia cells (27) . FLT3 proteins on the cell surface were internalized when exogenous FL stimulation was administered (3). Our results showed that an increased FLT3 protein levels in bone marrow mononuclear cells were related to the number of blast cells in the bone marrow, suggesting that FLT3 protein assay may be a useful biomarker for making leukemia prognosis.
In our cohort, the frequency of FLT3/ITD mutation was 25% in acute myeloid leukemia and 7% in acute lymphoid leukemia, which is consistent with findings of a Japanese study (23%) and Kottaridis et al (27%) (14, 15) . Our initial findings showed that Chinese patients with leukemia shared the same gene alternation as patients from different genetic backgrounds, suggesting a common mechanism for the pathogenesis of acute leukemia. We found a significant association between the presence of the FLT3/ITD mutation, a higher white blood cell count, a higher marrow blast percentage, and elevated serum LDH. This suggests that FLT3/ITD is an independent prognostic factor in acute leukemia. Other studies have also reported that high FLT3 expression levels were associated with an unfavorable prognosis (26, 28) .
In our study, the expression of FLT3 transcript in patients with tandem duplication was increased, but the increase was not significant. Ozeki et al (26) also reported the association between FLT3/ITD mutation and expression of FLT. The explanation for such an association is that expression levels of FLT3/ITD depend on the co-expression of the wild type and the mutant alleles. It has been detected that FLT3 expression levels were related to the relative proportions of wild type and mutant FLT3 (25) . Future analysis of FLT3 expression levels in patients with FLT3/ITD mutation should examine the relative fragments of wild type and mutant-FLT3.
To further assess the prognostic significance of FLT3/ITD mutation, we analyzed whether FLT3/ITD mutation influenced the complete remission rate of leukemia. The results showed that patients with FLT3/ITD had a little lower complete remission rate than patients without FLT3/ITD mutation, but the difference was not significant, which is in accordance with other studies (14, 15) . Lack of effect of FLT3/ITD mutation on the complete remission rate might be explained by a lack of effect of FLT3/ITD mutation on chemosensitivity of leukemic cells at diagnosis. Though it did not affect complete remission rate, FLT3 mutation has been found to predict relapse rate and overall survival (14, 29) . In fact, the presence of FLT3/ITD mutation has been suggested to have a major impact on long-term outcome (15) .
Recently, Stirewalt et al (30) has reported that the size of FLT3/ITD has prognostic significance in patients with acute myeloid leukemia. They showed that increased ITD size was associated with decreased overall survival and relapse free survival. We sequenced three PCR products of patients with acute leukemia with FLT3/ITD mutation, detecting the insertion sizes of 36 bp, 42 bp, and 57 bp. Insertion nucleotides >40 bp were regarded as large; two patients in our group had large size ITD mutation. The patient with 42 bp insertion died three months after two courses of chemotherapy. The patient with 57 bp insertion died 5 months after diagnosis. The third patient, with a secondary acute monocytic type of leuke-mia, experienced myelodysplastic syndrome with spontaneous splenic rupture and died 10 months later. It seems that larger ITD size is related to poorer clinical outcomes. However, more studies and patients are needed to confirm the effect of FLT3/ITD mutation size on prognosis.
In summary, our results suggest that FLT3 expression levels exhibit significant difference in various types of adult leukemia and that the presence of FLT3/ITD mutation is an independent prognostic factor for acute leukemia. Such results may provide a new target for leukemia therapy.
